US 11,858,999 B2
IL-17 receptor A antigen binding proteins
Joel E. Tocker, Issaquah, WA (US); Jacques J. Peschon, Seattle, WA (US); David Fitzpatrick, Karana Downs (AU); James F. Smothers, Quincy, MA (US); Christopher Mehlin, Seattle, WA (US); and Ai Ching Lim, Mercer Island, WA (US)
Assigned to AMGEN K-A, INC., Thousand Oaks, CA (US)
Filed by AMGEN K-A, INC., Thousand Oaks, CA (US)
Filed on Aug. 5, 2020, as Appl. No. 16/985,868.
Application 13/472,074 is a division of application No. 12/443,962, abandoned, previously published as PCT/US2007/021174, filed on Oct. 1, 2007.
Application 16/985,868 is a continuation of application No. 16/229,716, filed on Dec. 21, 2018, granted, now 11,180,564.
Application 16/229,716 is a continuation of application No. 15/058,738, filed on Mar. 2, 2016, granted, now 10,208,122, issued on Feb. 19, 2019.
Application 15/058,738 is a continuation of application No. 14/304,472, filed on Jun. 13, 2014, abandoned.
Application 14/304,472 is a continuation of application No. 13/472,074, filed on May 15, 2012, granted, now 8,790,648, issued on Jul. 29, 2014.
Claims priority of provisional application 60/969,895, filed on Sep. 4, 2007.
Claims priority of provisional application 60/873,072, filed on Dec. 5, 2006.
Claims priority of provisional application 60/827,882, filed on Oct. 2, 2006.
Prior Publication US 2020/0362045 A1, Nov. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 4 Claims
 
1. A method of treating scleroderma in a human patient in need thereof, which method comprises administering to the patient an effective amount of human monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds the human IL-17 receptor A, wherein the human monoclonal antibody comprises:
(a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 146, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 147, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 148, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 224, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 225, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 226; or
(b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40,
whereby the human monoclonal antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to IL-17 receptor A, and the scleroderma is treated in the human patient.